nifuralazine, nifurtimox, nimustine, ninorazole, nitrofurantoin, nitrogen mustards, oleomucin, oxolinic acid, pentamidine, pentostatin, phenazopyridine, phthalylsulfathiazole, pipobroman, prednimustine, prednisone, preussin, procarbazine, pyrimethamine, raltitrexed, rapamycin, rofecoxib, rosiglitazone, salazosulfapyridine, scriflavinium chloride, semustine streptozocine, sulfacarbamide, sulfacetamide, sulfachlopyridazine, sulfadiazine, sulfadicramide, sulfadimethoxine, sulfaethidole, sulfafurazole, sulfaguanidine, sulfaguanole, sulfamethizole, sulfamethoxazole, co-trimoxazole, sulfamethoxydiazine, sulfamethoxypyridazine, sulfamoxole, sulfanilamide, sulfaperin, sulfaphenazole, sulfathiazole, sulfisomidine, staurosporin, tamoxifen, taxol, teniposide, tertiposide, testolactone, testosteronpropionate, thioguanine, thiotepa, tinidazole, topotecan, triaziquone, treosulfan, trimethoprim, trofosfamide, UCN-01, vinblastine, vincristine, vindesine, vinblastine, vinorelbine, and zorubicin, preferably selected from the group consisting of auristatin, banoxantrone, bendamustine, chlorambucil, chaliceamycin, dynemycin A, maytansine, melphalan, mertansine, and neocazinostatin; or

wherein the anticancer drug is a proliferation inhibiting protein, preferably a cell cycle inhibitor or an antibody or antibody like binding protein that specifically binds to a proliferation promoting protein or a nucleic acid, preferably encoding a proliferation inhibiting protein or an antibody or antibody like binding protein that specifically binds to a proliferation promoting protein or a siRNA or DNAzyme.

15. The isolated targeted delivery system according to any of claim 1 to 12, wherein the active ingredient is a hypoxia-activated prodrug, preferably selected from the group consisting of benzotriazine N-oxides, apaziquone (EO9), tirapazamine (TPN), SN30000, PR-104A, TH-302, TH-4000, AQ4N.

16. The isolated targeted delivery system according to any of claims 1 to 15, wherein:

(i) the bond(s) between the iron binding protein(s) and the active ingredient comprised in the complex are covalent and/or non-covalent; and/or

(ii) the active ingredient comprised in the complex is entrapped/encapsulated by the iron binding protein or multimers thereof.

17. Method of preparation of the isolated targeted delivery system of claims 1 to 16 comprising steps of
    a) providing purified iron binding protein;
    b) covalently or non-covalently linking an active ingredient to and/or encapsulating an active ingredient in an iron binding protein;
    c) providing a $CD45^+$ leukocyte cell; and
    d) incubating the $CD45^+$ leukocyte cell in the presence of the iron binding protein produced in step b) until the $CD45^+$ leukocyte cell is at least partially loaded with the iron binding protein produced in step b).

18. The isolated targeted delivery system of any of claims 1-16 for use as a medicament.

19. A pharmaceutical composition comprising the isolated targeted delivery system of any of claims 1-16 and a pharmaceutically acceptable carrier and/or suitable excipient(s).

20. Use of an isolated targeted delivery system of any of claims 1-16 in the manufacture of a medicament for preventing/treating tumours, preferably a solid tumour, preferably breast cancer, pancreatic cancer, bladder cancer, lung cancer, colon cancer, or a tumour having hypoxic areas, inflammatory disease or ischemic areas in skin wounds or after organ infarctus (heart) or ischemic retina.